FLT3 and acute lymphoblastic leukemia: In vitro studies found FLT3-mutated cells sensitive to FLT3 inhibitors, and RAS and IL7R mutated primary cells sensitive to PI3K/mTOR inhibitors, thus demonstrating that these inhibitors might be incorporated in the treatment of ALL [69].